Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SEATTLE GENETICS INC /WA : Other Events, Financial Statements and Exhibits (form 8-K)

09/18/2020 | 07:00am EST

Item 8.01. Other Events.

On September 18, 2020, Seattle Genetics, Inc. and Astellas Pharma Inc. issued a press release announcing top-line results from the global, phase 3 EV-301 clinical trial, which compared PADCEV® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. A description of these top-line results is contained in the press release dated September 18, 2020, which is attached as Exhibit 99.1 to this current report and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



 99.1      Press Release of Seattle Genetics, Inc. and Astellas Pharma Inc. dated
         September 18, 2020

104      Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SEAGEN INC.
11/16Didi Chuxing, BYD roll out customized vans for ride-hailing service
RE
11/09SEAGEN : Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtua..
BU
11/05SEAGEN : Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the..
BU
11/02SEAGEN : to Host Virtual R&D Day on November 16, 2020
BU
10/30SEAGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
10/29SEATTLE GENETICS : 3Q Earnings Snapshot
AQ
10/29SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
10/29SEAGEN : Reports Third Quarter 2020 Financial Results
BU
10/29SEAGEN : Announces Closing of $1.0 Billion Stock Sale to Merck
AQ
10/28SEAGEN : Announces Closing of $1.0 Billion Stock Sale to Merck
BU
More news